STAT Plus: AstraZeneca and GSK drugs reduce risk of ovarian cancer returning, studies find
ODRA NOEL/WELLCOME
The results represent a step forward in treating a cancer that is diagnosed in 28,000 women annually in the U.S. and kills 14,000 a year.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario